Trigeminal Autonomic Cephalalgias: Treatment Recommendations
For SUNCT/SUNA (the most common trigeminal autonomic cephalalgias after cluster headache), lamotrigine is the recommended treatment based on available evidence, though the data quality is limited. 1
Clinical Recognition
Trigeminal autonomic cephalalgias are unilateral episodic pains that can be mistaken for trigeminal neuralgia but have distinct features:
- SUNCT: Short unilateral neuralgiform pain with conjunctival injection, tearing, and redness
- SUNA: Short unilateral neuralgiform pain with cranial autonomic features (unilateral tearing, miosis, sweating, nasal blockage/rhinorrhea, ear fullness)
- Attack characteristics: Rapid attacks lasting seconds to several minutes, up to 200 attacks daily, with no refractory period between attacks 1
- Pain quality: Sharp, stabbing, moderate to severe intensity 1
- Triggers: Mostly spontaneous, though some are light touch-evoked 1
Treatment Algorithm
Step 1: Acute Management
Currently, no established acute treatments exist for SUNCT/SUNA attacks due to their brief duration (seconds to minutes). The rapid onset and offset make typical abortive medications impractical.
Step 2: Preventive Treatment (Primary Approach)
First-line: Lamotrigine 1
- This anticonvulsant is the most consistently recommended preventive medication across guidelines
- Dosing typically ranges from 100-300 mg/day 2
- Evidence level is limited (no RCTs or large cohort data), but represents the best available option 1
Alternative options (when lamotrigine fails or is contraindicated):
- Gabapentin: 800-2700 mg/day 2
- Topiramate: 50-300 mg/day 2, 3
- Carbamazepine: 200-1600 mg/day 2
- Intravenous lidocaine: 1-4 mg/kg/hour for acute exacerbations to reduce attack flow 2
Step 3: Imaging Requirements
Obtain MRI including pituitary fossa 1 to exclude secondary causes, as the aetiology may differ from trigeminal neuralgia and structural lesions must be ruled out.
Critical Distinctions from Other Conditions
Do not confuse with trigeminal neuralgia:
- TACs have no refractory period between attacks (trigeminal neuralgia does)
- TACs have prominent autonomic features (tearing, conjunctival injection, nasal symptoms)
- TACs may have up to 200 attacks daily vs. multiple discrete episodes in trigeminal neuralgia
- Surgery has poorer outcomes in TACs compared to trigeminal neuralgia, likely due to different underlying pathophysiology 1
Important Caveats
Evidence limitations: There are currently no RCTs or large cohort studies for SUNA/SUNCT management 1. Treatment recommendations are based on case series, clinical experience, and extrapolation from related conditions.
Treatment resistance: These conditions are notoriously difficult to treat. If first-line lamotrigine fails, sequential trials of alternative anticonvulsants are warranted before considering more invasive options.
Quality of life impact: Despite the brief duration of individual attacks, the high frequency (up to 200/day) causes severe disability. Aggressive preventive treatment is justified even with limited evidence 4.
Hypothalamic involvement: Functional imaging suggests hypothalamic activation during attacks 5, 3, which may explain why treatments effective for other headache types often fail in TACs and why neuromodulation approaches targeting this region are being explored 6.